OncoMatch/Clinical Trials/NCT07774533
68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
Is NCT07774533 recruiting? Yes, currently enrolling (Sep 2026). This Early Phase 1 trial studies non-drug interventions for osteosarcoma.
This study aims to evaluate the safety, feasibility, and imaging performance of a novel 68Ga-labeled B7-H3 nanobody for immunoPET imaging in patients with osteosarcoma. Participants with suspected or histologically confirmed osteosarcoma will undergo 68Ga-B7-H3 nanobody PET/CT imaging according to the study protocol. Imaging findings will be compared with conventional imaging and, when available, histopathological results. The study will assess tracer biodistribution, tumor uptake, lesion detectability, and safety to determine the potential clinical value of B7-H3-targeted immunoPET for the diagnosis and evaluation of osteosarcoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Osteosarcoma
Demographics
Prior therapy
Must have received: systemic therapy
Relapsed or refractory disease following failure of first- or second-line systemic therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07774533 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 10 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages